Senores Pharmaceuticals Ltd

Net profit of Senores Pharmaceuticals rose 11.86% to Rs 17.83 crore in the quarter ended March 2025 as against Rs 15.94 crore during the previous quarter ended March 2024. Sales rose 11.49% to Rs 114.21 crore in the quarter ended March 2025 as against Rs 102.44 crore during the previous quarter ended March 2024. For the full year,net profit rose 86.20% to Rs 58.56 crore in the year ended March 2025 as against Rs 31.45 crore during the previous year ended March 2024. Sales rose 85.65% to Rs 398.25 crore in the year ended March 2025 as against Rs 214.52 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales114.21102.44 11 398.25214.52 86 OPM %17.0221.86 -22.5219.39 - PBDT25.9121.32 22 87.4134.97 150 PBT20.6817.61 17 70.5724.95 183 NP17.8315.94 12 58.5631.45 86 Powered by Capital Market - Live

Senores Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 15 May 2025.Powered by Capital Market - Live

Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (SPI), has signed agreement today to acquire the USFDA-approved Abbreviated New Drug Application ('ANDA') for Tramadol Tablets from APDM Pharmaceuticals (APDM). Tramadol is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The market size of Tramadol Tablet in the USA was ~USD 61.95 Mn (MAT December 2024)1 as per IQVIA and ~USD 119.09 Mn (MAT March 2025)2 as per the specialty data aggregator Symphony. The acquisition will be funded through the Initial Public Offer (IPO) proceeds raised by SPL. This is in line with the Objects of the IPO stated in the Red Herring Prospectus. Powered by Capital Market - Live

Shares of Wockhardt declined 2.15% to Rs 1,267 on the BSE. The market size of Topiramate tablet in the USA was USD 111.47 million (MAT December 2024) as per IQVIA. The acquisition will be funded through the initial public offer (IPO) proceeds raised by SPL. This is in line with the objects of the IPO stated in the red herring prospectus. Senores Pharmaceuticals (Senores) is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms. Wockhardt is a research based global pharmaceutical and Biotech Company. Powered by Capital Market - Live

Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (SPI), has signed agreement today to acquire the USFDA-approved Abbreviated New Drug Application (ANDA) for Topiramate HCl 25, 50, 100 and 200 mg tablets (Topiramate) from Wockhardt. Topiramate is indicated as a treatment of epilepsy and migraine. The market size of Topiramate Tablet in the USA was ~USD 111.47 Mn (MAT December 2024)1 as per IQVIA. The acquisition will be funded through the Initial Public Offer (IPO) proceeds raised by SPL. This is in line with the Objects of the IPO stated in the Red Herring Prospectus.Powered by Capital Market - Live

According to an exchange filing, the basket of acquired ANDAs consists of 13 USFDA-approved applications and one that is pending approval. The addressable market opportunity for these ANDAs in the U.S. is estimated at approximately USD 421 million (MAT December 2024), as per IQVIA, and around USD 1.13 billion (MAT September 2024), according to specialty data aggregator Symphony. The acquisition will be funded through the proceeds raised from Senores Pharmaceuticals' Initial Public Offer (IPO), in line with the objectives outlined in the Red Herring Prospectus. Swapnil Shah, Managing Director, Senores Pharmaceuticals, said, 'We are glad to announce the acquisition of a basket of products from Dr. Reddy's. It spans across various therapeutic areas with growing consumption. The portfolio consists of controlled substances and general categories of products. These products can be distributed through multiple/diverse channels, with large requirements in government, retail and specialty clinics. This portfolio of products significantly increases our product offering in the US, and it also has a significant value in other regulated and semi-regulated markets of the world.' Senores Pharmaceuticals (Senores) is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms. The company's consolidated net profit surged 142% to Rs 17.18 crore in Q3 FY25 as compared with Rs 7.10 crore in Q3 FY24. Net sales jumped 30.9% YoY to Rs 103.02 crore during the quarter ended 31st December 2024. Shares of Dr. Reddy's Laboratories rose 0.05% to Rs 1,120.40 on the BSE. Powered by Capital Market - Live

Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (SPI), has signed agreements today to acquire a basket of 14 Abbreviated New Drug Applications (ANDAs) from Dr. Reddy's Laboratories and its applicable affiliates. The basket acquired, comprises of 13 ANDAs, which are approved by the USFDA and 1 ANDA, which is pending approval from the USFDA. The addressable opportunity of the acquired ANDAs in the USA is approx. USD 421 Million (MAT December 2024) as per IQVIA and ~ approx USD 1.13 Billion (MAT September 2024)# as per the specialty data aggregator Symphony. The acquisition will be funded through the Initial Public Offer (IPO) proceeds raised by SPL. This is in line with the Objects of the IPO stated in the Red Herring Prospectus.Powered by Capital Market - Live

The facility spans approximately 230,000 sq. ft. and has an installed capacity of 100 metric tons per year. This marks their second API manufacturing plant, significantly enhancing their existing API manufacturing capabilities. Swapnil Shah, MD, SenoresPharmaceuticals, said, 'We are delighted to commence operations at our Greenfield state-of-the-art API facility at Mehsana. Commissioning of this API facility will help Senores broaden its offerings and strengthen its competitiveness in the regulated markets, especially in the CDMO/CMO business.' Senores Pharmaceuticals (Senores) is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms. The company's consolidated net profit surged 142% to Rs 17.18 crore in Q3 FY25 as compared with Rs 7.10 crore in Q3 FY24. Net sales jumped 30.9% YoY to Rs 103.02 crore during the quarter ended 31st December 2024. Shares of Senores Pharma rose 0.34% to Rs 550.40 on the BSE.Powered by Capital Market - Live

Senores Pharmaceuticals has commenced manufacturing activities at its greenfield active pharmaceutical ingredient (API) plant at Mehsana, Gujarat. Spread across approximately 230,000 sq. ft. with an installed capacity of ~100 Metric Tons per Annum, this is Senores' second API manufacturing facility. Powered by Capital Market - Live

Breckenridge Pharmaceutical, Inc., a U.S. subsidiary of Towa International that markets, distributes, and sells generic pharmaceuticals in the United States. Roflumilast is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis and a history of exacerbations. The market size of Roflumilast in the USA was approximately $32 million (MAT June 2024) as per IQVIA and around $46 million (MAT September 2024) as per the specialty data aggregator Symphony. The acquisition will be funded through the Initial Public Offer (IPO) proceeds raised by SPL. This is in line with the objects of the IPO stated in the red herring prospectus. Swapnil Shah, managing director, Senores Pharmaceuticals, said, 'We are excited to announce the acquisition of the Roflumilast tablet ANDA from Breckenridge Pharmaceutical, Inc. This strategic acquisition of Roflumilast Tablet ANDA, for which the manufacturing will be done locally at our US site, expands our portfolio into specialty distribution and also helps us establish a presence in the chronic bronchitis therapy area. This aligns with our strategic focus on identifying and entering a niche, under-penetrated generic formulations with an opportunity to serve the unmet needs in healthcare.' Senores Pharmaceuticals (Senores) is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms. The company's consolidated net profit surged 142% to Rs 17.18 crore in Q3 FY25 as compared with Rs 7.10 crore in Q3 FY24. Net sales jumped 30.9% YoY to Rs 103.02 crore during the quarter ended 31st December 2024.Powered by Capital Market - Live